
Around 60,000 people in the US get pancreatic cancer each year, with an estimated 50,000 deaths projected annually

TNBC is the most aggressive type of breast cancer and has historically been difficult to treat

The investigational once-weekly oral treatment could be the first long-acting pill for HIV prevention

The acquisition builds on Gilead’s oncology pipeline, focused on addressing areas of high unmet need

The US FDA has accepted a licence application for drug for relapsed/refractory multiple myeloma

The combination treatment showed a 35% reduction in the risk of disease progression

Wettan has served at Gilead for over 14 years

The company recently announced a $32bn investment in US R&D and manufacturing

This is the most common type of non-Hodgkin lymphoma worldwide

The drug treatment is being evaluated in several ongoing phase 3 trials

The study demonstrated strong clinical accuracy in differentiating pancreatic cancer patients from control subjects

Triple-negative breast cancer accounts for approximately 15% of all cases of the disease